Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Fennec Pharmaceuticals (FENC) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Fennec Pharmaceuticals' Cash from Financing Activities rose 43125.0% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 34007.4%. This contributed to the annual value of -$13.6 million for FY2024, which is 30510.7% down from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Cash from Financing Activities stood at $1.7 million, which was up 43125.0% from -$284000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Cash from Financing Activities high stood at $19.8 million for Q3 2022, and its period low was -$12.2 million during Q4 2024.
  • Over the past 4 years, Fennec Pharmaceuticals' median Cash from Financing Activities value was $201000.0 (recorded in 2023), while the average stood at $1.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 118666.67% in 2023, then crashed by 68652.85% in 2024.
  • Over the past 4 years, Fennec Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $824000.0 in 2022, then surged by 595.39% to $5.7 million in 2023, then plummeted by 313.12% to -$12.2 million in 2024, then soared by 114.32% to $1.7 million in 2025.
  • Its Cash from Financing Activities stands at $1.7 million for Q3 2025, versus -$284000.0 for Q2 2025 and $359000.0 for Q1 2025.